Birgit Thelen-Coco
Investor Relations Contact at SCT-Spinal Cord Therapeutics GmbH
Profile
Birgit Thelen-Coco is currently the Head of Communications at SCT-Spinal Cord Therapeutics GmbH.
Birgit Thelen-Coco active positions
Companies | Position | Start |
---|---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Investor Relations Contact | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Commercial Services |
- Stock Market
- Insiders
- Birgit Thelen-Coco